October, 2009:

• Phase 3 study of eribulin for locally advanced or metastatic breast cancer
• Dysport available for the treatment of cervical dystonia
• Phase 2b study of cariprazine for schizophrenia
• Accusure Insulin Syringes recalled
• Arzerra approved for the treatment of chronic lymphocytic leukemia
• Needle-protected EpiPen and EpiPen Jr. Auto-Injector launched for anaphylaxis
• Emergency use authorization (EUA) issued for peramivir for H1N1 influenza infection
• FDA warns of progressive multifocal leukoencephalopathy (PML) with Rituxan
• Phase 3 study of Nexavar for the treatment of non-responsive thyroid cancer
• Phase 2a study of AR-12286 for treatment of glaucoma and ocular hypertension
• Dose response study of PH20 for the management of diabetes
• Ketorolac tromethamine injection recalled
• Additional data reported in Phase 2 trial of bavituximab for advanced breast cancer
• Updated interim recommendations for 2009 H1N1 influenza vaccination and treatment for HIV-infected patients
• Phase 2a study of AGS-004 for the immunotherapeutic treatment of HIV infection
• FDA fast track designation granted for Perceiva for diabetic macular edema
• Fluarix influenza vaccine approved for pediatric use
• Votrient approved for advanced renal cell cancer
• Colcrys gains indication for gout flare prevention
• Phase 2 study of SB-509 for the treatment of diabetic neuropathy
• Elitek approved for management of plasma uric acid levels in cancer patients
• Concentrated Prolastin-C approved for alpha1-antitrypsin (AAT) deficiency
• Twynsta approved for the treatment of hypertension
• Micardis 80mg gains indication for cardiovascular risk reduction
• Phase 2b study of arbaclofen placarbil for treatment of GERD
• Phase 2 study of Arikace for treatment of pseudomonas lung infections
• Cervarix approved for prevention of HPV-associated cervical cancer
• Gardasil approved for the prevention of genital warts in boys and young men
• Colcrys available for the treatment of acute gout flares and familial Mediterranean fever (FMF)
• Anaphylactic-type reactions possible with Dexferrum; boxed warning updated
• FDA warns of unapproved and illegal H1N1 (swine) influenza products on Internet
• Crestor approved for pediatric patients with Heterozygous Familial Hypercholesterolemia
• Phase 1/2 study of Excellarate for the treatment of non-healing diabetic foot ulcers
• FDA launches Web page of disposal instructions for select medicines
• Interim analysis of H1N1 (swine) influenza vaccine in infants and children
• NCCN publishes updated cervical screening guidelines
• FDA halts marketing of unapproved codeine sulfate tablets
• Phase 1 study of MBX-2982 for the treatment of type 2 diabetes
• FDA warns that Relenza is not to be administered by nebulizer or mechanical ventilator
• Berinert approved for abdominal or facial attacks of hereditary angioedema (HAE)
• Hiberix Haemophilus influenzae type b (Hib) vaccine available
• H. pylori Eradication Options for Peptic Ulcer Disease
• Evaluation of Insomnia
• Onsolis available soon for breakthrough cancer pain
• Phase 2b study of RLY5016 for treatment of hyperkalemia associated with heart failure
• Welchol gains pediatric indication
• Isopure Plus protein drinks available for nutritional supplementation
• Evaluation of Hypertension
• Folotyn available for peripheral T-cell lymphoma (PTCL)
• Phase 3 study of DM-1796 for the treatment of postherpetic neuralgia (PHN)
• Phase 2 study of bavituximab for the treatment of non-small cell lung cancer (NSCLC)
• Phase 3b study of Onglyza in combination with metformin for type 2 diabetes
• Phase 3 study of dapagliflozin in combination with metformin for type 2 diabetes
• Phase 3 study of Afresa for the treatment of type 2 diabetes
• Mirena approved for heavy menstrual bleeding
• FDA provides update of change to heparin potency
• FC2 Female Condom available
• BenzEFoam available for acne vulgaris